Pyxis Oncology, Inc. (PYXS): Price and Financial Metrics
PYXS Price/Volume Stats
| Current price | $3.82 | 52-week high | $6.85 |
| Prev. close | $4.16 | 52-week low | $1.35 |
| Day low | $3.80 | Volume | 5,457,100 |
| Day high | $4.31 | Avg. volume | 654,364 |
| 50-day MA | $3.71 | Dividend yield | N/A |
| 200-day MA | $4.06 | Market Cap | 227.16M |
PYXS Stock Price Chart Interactive Chart >
Pyxis Oncology, Inc. (PYXS) Company Bio
Pyxis Oncology, Inc., a preclinical stage biotechnology company, engages in the development of antibody-drug conjugates (ADCs) and monoclonal antibody (mAb) immunotherapies to treat cancers. Its preclinical products pipeline includes PYX-201, a site-specific investigational ADC targeting onco-fetal fibronectin extradomain-B for the treatment of non-small cell lung cancer; PYX-202, a site-specific investigational ADC targeting delta like non-canonical notch ligand 1 to treat small cell lung cancer, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational site-specific ADC targeting CD123 for the treatment of acute myeloid leukemia and other blood cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
PYXS Price Returns
| 1-mo | 8.83% |
| 3-mo | 2.96% |
| 6-mo | 0.26% |
| 1-year | 172.86% |
| 3-year | -69.14% |
| 5-year | N/A |
| YTD | 112.22% |
| 2023 | 34.33% |
| 2022 | -87.78% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...